|Protocol||Trial Name and Objective|
Psychological Interventions for Gynecologic Cancer
Very little is known in the psycho-oncology literature about why psychological interventions are effective or for how long these interventions exert an impact. Given many cancer patients experience recurrence and/or progression, it is important to know whether our relatively brief interventions facilitate how patients cope with this most-feared medical event. From a theoretical perspective, the study will advance our understanding of the mechanisms for change for two common treatment approaches, supportive and cognitive behavioral therapies.
Primary Objective: To evaluate the efficacy of CCI, SC, and Usual Care (UC) on patients' long-term general and cancer-specific psychological adaptation, concerns about recurrence/progression, and quality of life, and to determine whether intervention effects are moderated by disease recurrence.
Secondary Objective: To evaluate the cognitive, social, emotional, and behavioral processes which mediate CCI and SC's effects on patients' long-term general and cancer-specific psychological adaptation, concerns about recurrence/progression, and quality of life.
Revisiting the Methods to Calculate Carboplatin Dose in Women with Gynecologic Cancers A Retrospective Chart Review
The purpose of this study is to evaluate the precision and accuracy of creatinine clearance estimation by the Cockcroft-Gault, Jelliffe, and Wright formula and determine which formula is the best substitute for the gold standard of GFR estimation for the purpose of carboplatin dosing in a gynecologic oncology population.
Dietary Inflammatory Index and Ovarian Cancer Risk
Our study aims to evaluate the role of a new dietary inflammatory index in predicting ovarian cancer risk. We will also compare results with those obtained with the Healthy Eating Index.
NSABP B-55: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Primary Objective The primary objective is to assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS)
To assess the safety and tolerability of adjuvant treatment with olaparib
1.To assess the effect of adjuvant treatment with olaparib on overall survival (OS)
2.To assess the effect of adjuvant treatment with olaparib on Distant Disease Free Survival (DDFS)
3.To assess the effect of adjuvant treatment with olaparib on the incidence of new invasive breast primary cancer and/or new epithelial ovarian cancer
4.To assess the effect of olaparib on patient reported outcomes using the FACIT fatigue scale and EORTC QLQ-C30 QoL scale
5.To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future germline BRCA mutation assays (gene sequencing and large rearrangement analysis)
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer
The primary objective of the Phase 1b portion of this study is to determine the recommended Phase 2 dose of LY2228820 that can be safely administered in combination with gemcitabine and carboplatin.
The primary objective of the Phase 2 portion of this study is to compare the progression-free survival in patients treated with LY2228820 plus gemcitabine and carboplatin versus placebo plus gemcitabine and carboplatin.
The secondary objectives of the study are to evaluate:
1. Change in tumor size, CA125 (serum biomarker for ovarian cancer), overall response rate, and overall survival (OS)
2. Safety and tolerability of the combination: LY2228820 plus gemcitabine and carboplatin
3. Pharmacokinetics (PK) of LY2228820 and evaluation for effect of LY2228820 on the PK of gemcitabine, its metabolite (dFdU), and carboplatin
4. Biomarkers related to p38 MAPK pathway activity and the pathogenesis of ovarian cancer
5. Patient-reported outcomes for patients enrolled in the Phase 2 portion of the study
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)
The aim of this study is to test the potential benefit of the addition of adjuvant chemotherapy following completion of primary chemoradiation for patients with locally advanced cervical cancer.
The primary objective will be to determine if the addition of adjuvant chemotherapy to standard cisplatin-based chemoradiation improves overall survival.
Secondary objectives will be to determine:
Progression-free survival rates
Acute and long-term toxicities
Patterns of disease recurrence
The association between radiation protocol compliance and outcomes
Patient quality of life, including psycho-sexual health
Tertiary objectives will be to determine:
The association between the results of a follow-up PET scan performed 4 - 6 months post completion of chemo-radiation and outcomes for all patients in the trial
Biological predictors of patients outcomes based on translational laboratory studies of blood and tissue specimens
GOG-0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?
1.11 To determine if women who are disease-free after successfully completing
primary and potential consolidation/maintenance, therapy for Stage II-IV
ovarian, fallopian tube or primary peritoneal cancer and who are randomized to
a healthy lifestyle intervention, will have significantly increased progression free survival compared to similar women who are randomized to a usual care comparison group.
1.2 Secondary Objectives
1.21 To determine if women who are randomized to the study intervention will have:
1.211 Improved general quality of life as measured by the General Health
subscale of RAND-36.
1.212 Improved physical and bowel functioning as measured by the Physical
Functioning subscale of RAND-36 and the GSRS-IBS, compared to
women who are randomized to usual care.
1.3 Exploratory Objectives:
1.31 To perform a pilot assessment at baseline, 6, 12, and 24 month dietary
biomarkers in a sub-sample of the study population to estimate compliance with
the healthy lifestyle intervention and to explore the relationship between
carotenoid exposure and progression free survival from ovarian cancer.
1.32 To examine patient compliance with the healthy lifestyle intervention and to assess which types of patients are more likely to be compliant with the healthy lifestyle intervention and whether progression-free survival is better among compliant individuals.
1.33 To explore the impact of the intervention on other aspects of quality of life such as: pain, role limitations due to physical health and emotional problems, mental health, vitality, and social functioning as measured by the corresponding subscales of the RAND-36.
1.34 To explore the impact of the intervention on bowel functioning as measured
with the GSRS-IBS subscales.